Michelle Hoiseth, Chief Data Officer for Parexel and Dr. GunjanRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering to unlock the potential of phytocannabinoids in designing medical therapies.
ESCHBORN, Germany, Oct 25th, 2021 – Innoplexus, a global leader in AI-based drug discovery and development; and DrD, an innovative biotechnology company focused on phytocannabinoids, are partnering to accelerate the clinical development and market authorization of novel medications based on phytocannabinoids and other phytochemicals, leveraging Innoplexus’ leading AI technology.
The increasing global acceptance and usage of cannabis as a pharmaceutical product continues to spotlight the unique benefits of phytocannabinoids in designing treatments for a range of diseases including, but far from limited to anxiety, pain, sleep disorders, Parkinson’s disease, and Schizophrenia. The reality on the ground is complicated – many people use many different cannabis-based products to treat numerous ailments and the evidence to support differentiated usage as effective is highly unorganized. The partnership will seek to identify the most promising and targetable indications, rationalize single and multi-component phytochemical formulations for clinical testing, and expedite the execution of clinical trials. This partnership aims to accelerate the approvals of the most promising compounds, bringing them to patients in a shorter, more economical timeframe.
“The cannabis plant produces a multitude of bioactive compounds which offer significant benefits for designing safe and effective pharmaceuticals,” explains Pierre Debs, PhD., Managing Partner & Founder of DrD GmbH. “Together with Innoplexus, we will rapidly validate existing scientific evidence, identify gaps in knowledge, fill those gaps, and design, execute and bring to market clinically proven cannabis-based medical products. The partnership with Innoplexus will allow us to rapidly determine the extent to which the endocannabinoid system can be modulated to restore homeostasis, leading to the development of personalized therapies targeted to treat specific indications.” Pavel Kubu, M.D., DrD GmbH Managing partner & founder adds: “Utilizing state of the art AI and machine learning algorithms bring to the development of cannabinoid medicines much-needed tools with profound insights into the complex bioactivity of phytocannabinoids on the endocannabinoid system and the ability to explore patient-specific characteristics for increased efficiency of precision treatments especially for chronic conditions”.
The partnership will leverage the artificial intelligence platform of Innoplexus, which can search terabytes of structured and unstructured data and extract relevant life sciences information. Innoplexus’ Life Science Language Processing™, with a self-learning Ontology of over 30 million biomedical concepts and terms, will be used to identify the links between the endocannabinoid systems, phytocannabinoids, targets, and pathways and diseases, and to further investigate these connections to determine the extent to which the endocannabinoid system can be directly modulated.
Vatsal Agarwal, SVP Real World Data & Analytics at Innoplexus, highlights the importance of leveraging AI-driven insights to power drug discovery and development for phytocannabinoids: “Using Innoplexus AI and Ontology, we can collect and structure the existing world of research on phytocannabinoids and identify the most promising avenues for further research at incredible speed.”
Both DrD and Innoplexus look forward to deconvoluting and rationalizing the existing data to harness the potential of phytocannabinoids and to improve treatment opportunities for a broad spectrum of patients.
Innoplexus is a leading global AI-based platform for drug discovery and development with over 250 employees and 110+ patent applications including 40 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus’ solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unprecedented speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.
DrD GmbH is a drug discovery company leveraging advanced in silico & biotechnologies to rationalize the utilization and expedite the availability of novel cannabis-based medical products. Founded in 2020 in Frankfurt am Main, Germany, DrD GmbH exploits >50 years’ experience in modern Medicine, Scientific Research, Cannabis Industry Expertise, Biotech and Digital technologies to rapidly design, clinically trial and bring to market non-toxic and efficient phytocannabinoid based medications.
https://innoplexus-marketing.s3.amazonaws.com/video/Parexel+Teaser+vParexel.mp4?_=1 Michelle Hoiseth, Chief Data Officer for Parexel and Dr. Gunjan Bhardwaj, CEO Innoplexus discuss the importance of access to the…